2. Search Result
Search Result
Results for "

raloxifene

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

2

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13738
    Raloxifene
    Maximum Cited Publications
    9 Publications Verification

    Keoxifene; LY156758 free base; LY139481

    		 Estrogen Receptor/ERR Cancer
    Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .
    <em>Raloxifene</em>
  • HY-135596
    Raloxifene dimethyl ester hydrochloride

    Diacyl-raloxifene hydrochloride; raloxifene diacyl analog

    		 Others
    Raloxifene dimethyl ester hydrochloride is an analog of Raloxifene, extracted from patent US5464845A, compound 28 .
    <em>Raloxifene</em> dimethyl ester hydrochloride
  • HY-135580
    Raloxifene Bismethyl Ether

    		Drug Metabolite Endocrinology
    Raloxifene Bismethyl Ether is a metabolite of Raloxifene and an estrogen receptor inactive compound on which both hydroxyl groups are absent .
    <em>Raloxifene</em> Bismethyl Ether
  • HY-135580A
    Raloxifene Bismethyl Ether hydrochloride

    		Drug Metabolite Endocrinology
    Raloxifene Bismethyl Ether hydrochloride is a metabolite of Raloxifene and an estrogen receptor inactive compound on which both hydroxyl groups are absent .
    <em>Raloxifene</em> Bismethyl Ether hydrochloride
  • HY-135590
    Raloxifene 4-Monomethyl Ether

    		Estrogen Receptor/ERR
    Raloxifene 4-Monomethyl Ether (Compound 37) is a Raloxifene derivative that inhibits estrogen receptor α. Raloxifene 4-Monomethyl Ether inhibits MCF-7 cells with an IC50 of 1 μM and a pIC50 of 6 .
    <em>Raloxifene</em> 4-Monomethyl Ether
  • HY-135584
    Raloxifene 6-Monomethyl Ether

    		Estrogen Receptor/ERR
    Raloxifene 6-Monomethyl Ether (Compound 7) is a Raloxifene derivative that inhibits estrogen receptor α. Raloxifene 4-Monomethyl Ether inhibits MCF-7 cells with an IC50 of 250 nM and a pIC50 of 6.6 .
    <em>Raloxifene</em> 6-Monomethyl Ether
  • HY-135581
    Raloxifene 6-glucuronide

    		Estrogen Receptor/ERR Endocrinology
    Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .
    <em>Raloxifene</em> 6-glucuronide
  • HY-135582
    Raloxifene 4'-glucuronide

    		Estrogen Receptor/ERR Endocrinology
    Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC50 of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .
    <em>Raloxifene</em> 4'-glucuronide
  • HY-13738S
    Raloxifene-d4

    		Isotope-Labeled Compounds Estrogen Receptor/ERR Cancer
    Raloxifene-d4 is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
    <em>Raloxifene</em>-d4
  • HY-13738S2
    Raloxifene-d4 hydrochloride

    		Isotope-Labeled Compounds Estrogen Receptor/ERR Cancer
    Raloxifene-d4 (hydrochloride) is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
    <em>Raloxifene</em>-d4 hydrochloride
  • HY-13738S3
    Raloxifene-d10

    		Isotope-Labeled Compounds Estrogen Receptor/ERR Cancer
    Raloxifene-d10 is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
    <em>Raloxifene</em>-d10
  • HY-135586
    Raloxifene N-Oxide

    		Drug Metabolite Metabolic Disease
    Raloxifene N-Oxide is a Raloxifene oxidative degradation product .
    <em>Raloxifene</em> N-Oxide
  • HY-135581S1
    Raloxifene 6-glucuronide-d4 lithium

    		Estrogen Receptor/ERR Endocrinology
    Raloxifene 6-glucuronide-d4 (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[1][2][3].
    <em>Raloxifene</em> 6-glucuronide-d4 lithium
  • HY-135582S1
    Raloxifene 4'-glucuronide-d4 lithium

    		Estrogen Receptor/ERR Endocrinology
    Raloxifene 4'-glucuronide-d4 (lithium) is deuterium labeled Raloxifene 4'-glucuronide. Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC50 of 370 μM. [1][2]. Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[3].
    <em>Raloxifene</em> 4'-glucuronide-d4 lithium
  • HY-135588
    Raloxifene 6,4'-Bis-β-D-glucuronide

    		Drug Metabolite Metabolic Disease
    Raloxifene 6,4'-Bis-β-D-glucuronide (compound IV) is a metabolite of Raloxifene. Raloxifene is a selective estrogen receptor antagonist for the prevention of osteoporosis .
    <em>Raloxifene</em> 6,4'-Bis-β-D-glucuronide
  • HY-13738A
    Raloxifene hydrochloride
    Maximum Cited Publications
    9 Publications Verification

    Keoxifene hydrochloride; LY156758; LY139481 hydrochloride

    		 Estrogen Receptor/ERR Autophagy Endocrinology Cancer
    Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active estrogen receptor modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue .
    <em>Raloxifene</em> hydrochloride
  • HY-13738AR
    Raloxifene hydrochloride (Standard)

    Keoxifene (hydrochloride)(Standard); LY156758(Standard); LY139481 hydrochloride (Standard)

    		 Estrogen Receptor/ERR Autophagy Endocrinology Cancer
    Raloxifene (hydrochloride) (Standard) is the analytical standard of Raloxifene (hydrochloride). This product is intended for research and analytical applications. Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation?selective and orally active estrogen receptor modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue .
    <em>Raloxifene</em> hydrochloride (Standard)
  • HY-13738S4
    Raloxifene-d10-1

    Keoxifene-d10; LY156758(free base)-d10; LY139481-d10

    		 Estrogen Receptor/ERR Cancer
    Raloxifene-d10-1 is the deuterium labeled Raloxifene[1]. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[2].
    <em>Raloxifene</em>-d10-1
  • HY-135587
    4'-tert-Butyldimethylsilyl-6-hydroxy Raloxifene

    		Others Others
    4'-tert-Butyldimethylsilyl-6-hydroxy Raloxifene (Compound 4) is a reaction product of Raloxifene with tertbutyldimethylsilyl chloride. 4'-tert-Butyldimethylsilyl-6-hydroxy Raloxifene is used to synthesize Raloxifene 6-glucuronide .
    4'-tert-Butyldimethylsilyl-6-hydroxy <em>Raloxifene</em>
  • HY-135595
    6-Raloxifene-β-D-glucopyranoside

    		Estrogen Receptor/ERR Drug Metabolite Metabolic Disease
    6-Raloxifene-β-D-glucopyranoside, a derivative of Raloxifene, is a benzothiophene glucuronidated at the 6' postion. 6-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 6-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 6'-Raloxifene-β-D-glucopyranoside, compound Ia, is extracted from patent US5567820A .
    6-<em>Raloxifene</em>-β-D-glucopyranoside
  • HY-135594
    4'-Raloxifene-β-D-glucopyranoside

    		Estrogen Receptor/ERR Metabolic Disease
    4'-Raloxifene-β-D-glucopyranoside, a metabolite of Raloxifene, is a benzothiophene glucuronidated at the 4' postion. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 4'-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 4'-Raloxifene-β-D-glucopyranoside, example 5, is extracted from patent US5567820A .
    4'-<em>Raloxifene</em>-β-D-glucopyranoside
  • HY-135591
    Methyl Raloxifene 4'-(2,3,4-Tri-O-acetyl-β-D-glycopyranuronate)

    		Others Others
    Methyl Raloxifene 4'-(2,3,4-Tri-O-acetyl-β-D-glycopyranuronate) is an analogue of Raloxifene 4'-glucuronide.
    Methyl <em>Raloxifene</em> 4'-(2,3,4-Tri-O-acetyl-β-D-glycopyranuronate)
  • HY-135585
    LY88074

    		Others Endocrinology
    LY88074 (Compound 88074) is a Raloxifene analog lacking the basic side chain. Raloxifene is a selective estrogen receptor modulator, and reduces fracture risk at least in part by improving the mechanical properties of bone in a cell- and estrogen receptor-independent manner .
    LY88074
  • HY-135589
    7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene

    		Others Cancer
    7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene is a liver receptor homolog-1 (LRH-1) antagonist with an IC50 of 3.1 μM .
    7-[4-(2-Piperidinyl)ethoxy]benzoyl <em>Raloxifene</em>
  • HY-13556
    Arzoxifene

    LY353381; SERM III

    		 Estrogen Receptor/ERR Metabolic Disease
    Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator with a fixed ring structure similar to raloxifene. Arzoxifene has minimal side effects with powerful antiestrogenic effects on breast cancer and endometrium, with equally strong favorable estrogenic effects on bone and lipid profile .
    Arzoxifene
  • HY-116896
    LY117018

    		Estrogen Receptor/ERR Cancer
    LY117018, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 exerts antiproliferative effects on breast cancer cell lines .
    LY117018
  • HY-116896A
    LY117018 TFA

    		Estrogen Receptor/ERR Cancer
    LY117018 TFA, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 TFA exerts antiproliferative effects on breast cancer cell lines .
    LY117018 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: